MedTrace Logo

Assessing the Effects of a Cannabidiol Derived From Hemp Supplement in Healthy Adults

NCT05212402 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2022-11-01

No results posted yet for this study

Summary

The purpose of this prospective, randomized, double-blind, placebo-controlled trial is to assess the physiological, biochemical, and psychometric impacts of a brand-specific hemp-derived cannabidiol product in a sample of healthy adults.

Conditions

  • Healthy
  • Safety Issues

Interventions

DIETARY_SUPPLEMENT

Cannabinol

Prospective,1:1 randomization and stratified by birth sex, and double-blinded to the condition of subjects.

OTHER

Placebo

Prospective,1:1 randomization and stratified by birth sex, and double-blinded to the condition of subjects.

Sponsors & Collaborators

  • Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

    collaborator NETWORK

  • University of South Carolina

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-18
Primary Completion
2022-09-30
Completion
2022-10-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05212402 on ClinicalTrials.gov